Remove Clinical Trials Remove Data Remove Patients
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.

article thumbnail

Clinical Trial: Oral THC Administration Associated with Opioid-Sparing Effects

NORML

Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. Sixty-six patients participated in the study. Half of the participants received dronabinol and the other half did not.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First Ever Clinical Trial for Cannabis Migraine Treatment is Underway

Veriheal

However, there has not been a clinical trial assessing the efficacy of cannabis for migraines, at least not until now. Science Alert has announced that the first clinical trial for cannabis as a migraine treatment is underway. The First Clinical Trial for Migraines and Cannabis.

article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug

Cannabis Law Report

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.

article thumbnail

Clinical Trial: Transdermal Application of CBD Effective in Patients with Myofascial Pain

NORML

The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine. Subjects receiving treatment reported no adverse effects.

article thumbnail

Clinical Trial: CBD Administration Reduces Heroin Cravings

NORML

The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry. ” In observational models , patients with legal access to cannabis typically reduce or eliminate their use of opioids.